广药广开合作创投基金完成备案，首期实缴出资1.2亿元

Core Viewpoint - The company Baiyunshan has established a new venture capital fund, Guangzhou Guangyao Guangkai Venture Capital Fund, with a total initial capital contribution of 120 million yuan, aimed at enhancing its investment in innovative pharmaceuticals and medical devices [2][5]. Group 1: Fund Establishment and Registration - Baiyunshan announced the completion of the business registration and acquisition of a business license for the Guangzhou Guangyao Guangkai Venture Capital Fund in January 2026 [2][5]. - The fund has been registered with the Asset Management Association of China and has obtained the Private Investment Fund Registration Certificate [5]. Group 2: Investment Details - The total initial capital contribution for the fund is 120 million yuan, with Baiyunshan's subsidiary contributing 9.75 million yuan [3][6]. - The fund's capital structure includes 50% from Guangkai Fund, 48.75% from Guangyao Phase II Fund, and 1.25% from Guangyao Capital [5]. Group 3: Strategic Implications - The investment aligns with the strategic direction of Guangyao Phase II Fund, aiming to expand investment scale, diversify risks, and accelerate investment pace [5]. - Baiyunshan intends to strengthen its position in cutting-edge biomedicine fields through early-stage investments in promising companies, facilitating technological upgrades and extending its value chain [5]. Group 4: Overall Investment Situation - Baiyunshan's total investment in various private equity funds has reached 587 million yuan, with the largest investment being 390 million yuan in the Guangzhou Guangyao Chuantou Venture Capital Fund [6].